Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.37 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14131571 | 0.93 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA2 | |
| SCHEMBL4961430 | 0.93 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA2 | |
| SCHEMBL4961425 | 0.93 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA2 | |
| SCHEMBL3221184 | 0.87 | CHRNB2 (0.47) | CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8507152 | 0.85 | SLC6A2 (0.46) | CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7411409 | 0.84 | CHRNB4 (0.36) | CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7668971 | 0.84 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL6233084 | 0.84 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL7406929 | 0.84 | CHRNB4 (0.36) | CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8550383 | 0.82 | GPR119 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176826-A1 | Pyridine Compounds For Combating Arthropod Pests and Nematodes | BASF AKTIENGESELLSCHAFT (DE) | 2008-07-24 | — | — | US | disclosed |
| EP-1891045-A2 | PYRIDINE COMPOUNDS FOR COMBATING ARTHROPOD PESTS AND NEMATODES | BASF AKTIENGESELLSCHAFT (DE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006125641-A2 | PYRIDINE COMPOUNDS FOR COMBATING ARTHROPOD PESTS AND NEMATODES | BASF AKTIENGESELLSCHAFT (DE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176826-A1 | Pyridine Compounds For Combating Arthropod Pests and Nematodes | C5, CHRM1, ACHE | CHRNB2 679/4885CHRNA4 300/4885SLC6A2 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.